市場調查報告書
商品編碼
1151889
全球醫用大麻市場規模研究與預測,按配方類型(膠囊,油,其他),應用(慢性疼痛,關節炎,偏頭痛,癌症,其他用途)、區域分析2022-2029Global Medical Marijuana Market Size study & Forecast, by Formulation Type (Capsules, Oils, and Other Formulation Types) by Application (Chronic Pain, Arthritis, Migraine, Cancer, and Other Applications) and Regional Analysis, 2022-2029 |
2021 年全球醫用大麻市場價值約為 110 億美元,預計在 2022-2029 年的預測期內將以超過 21.06% 的增長率增長。
醫用大麻,也稱為醫用大麻,源自植物大麻,也用於治療疾病和某些病症,例如癌症、慢性疼痛、精神疾病和疼痛管理。。醫用大麻有兩種類型:來自西半球的大麻和來自中亞和南亞的大麻。市場增長的主要推動力是人們越來越意識到醫用大麻的好處,整個地區的大麻合法化程度不斷提高,以及 FDA 對醫用大麻產品的批准不斷增加。
2018 年,FDA 批准了第一種含有源自大麻的活性成分的藥物,用於治療癲癇。 Epidiolex(大麻二酚)[CBD]口服溶液獲得批准用於治療兩種嚴重且罕見的癲癇相關癲癇發作:Lennox-Gastaut 綜合徵和 Dravet 綜合徵。 2018年1月,澳大利亞政府允許澳大利亞大麻生產商向全球醫用大麻市場出口醫用大麻及其產品。此外,隨著研發活動的增加,創新產品的開發將在預測期內為市場創造有利可圖的機會。然而,關於大麻使用的複雜監管結構將阻礙整個 2022-2029 年預測期內的市場增長。
全球醫用大麻市場研究考慮的主要區域包括亞太地區、北美、歐洲、拉丁美洲和世界其他地區。由於美國大麻合法化的進展,北美已成為市場份額第一的地區。由於大麻合法化程度的提高以及可支配收入增加、社會接受度和消費者對產品益處的了解等因素,預計亞太地區在預測期內將呈現高速增長。
本報告中包含的主要市場參與者包括:
市場的最新發展
全球醫用大麻市場研究範圍
歷史數據:2019-2020-2021
基準估計年份:2021
預測時間:2022-2029
報告涵蓋的收入預測、公司排名、競爭格局、增長因素、趨勢
目標細分市場製劑類型、應用、地區
區域範圍北美、歐洲、亞太地區、拉丁美洲、世界其他地區
購買後可免費定制覆蓋率報告(相當於最多 8 個分析師小時)。添加或更改國家、地區、細分範圍*
這項研究的目的是定義近年來各個細分市場和國家的市場規模,並預測他們在未來幾年的價值。該報告旨在捕捉被調查國家工業的定性和定量方面的情況。
它還提供了關鍵方面的詳細信息,例如決定市場未來增長的驅動因素和挑戰。此外,它還包含供利益相關者投資的微觀市場潛在機會,以及對主要參與者的競爭格局和產品供應的深入分析。市場的詳細細分和子細分如下所述。
按配方類型
膠囊
石油
其他配方類型
按申請
慢性疼痛
關節炎
偏頭痛
癌症
其他用途
按地區
北美
美國
加拿大
歐洲
英國
德國
法國
西班牙
意大利
其他歐洲
亞太地區
中國
印度
日本
澳大利亞
韓國
其他亞太地區
拉丁美洲
巴西
墨西哥
世界其他地區
Global Medical Marijuana Market is valued approximately at USD 11.0 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 21.06% over the forecast period 2022-2029. Medical marijuana, also referred to as medical cannabis, is derived from the Cannabis sativa plant which is also used to treat a disease or specific symptom such as cancer, chronic pain, mental disorders, and manage pain. Cannabis Sativa and Cannabis Indica, which come from the western hemisphere and central and south Asian regions, respectively, are the two types of medical marijuana. The key factors driving the market growth is rising awareness about benefits of medical marijuana, growing legalization of cannabis across region and growing FDA approvals for medicinal cannabis products.
In 2018, FDA approved the first drug comprising of an active component derived from marijuana for treating epilepsy. Epidiolex (cannabidiol) [CBD] in oral solution was granted this approval to treat seizures related to two severe and rare forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome. In January 2018, the Australian Government allowed marijuana producers in the country to export medical marijuana and its products to the global medical marijuana market. Also, innovative product development with growing R&D activities will create lucrative opportunities for the market during forecast period. However, the complex regulatory structure for the usage of cannabis stifles market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Medical Marijuana Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the rising cannabis legalization in the U.S. This is one of the key factors contributing to its growing demand. Asia Pacific is also anticipated to exhibit highest growth rate over the forecast period, owing to factors such as increasing legalization of cannabis as well as an increase in disposable income, social acceptance, and consumer understanding of the product's advantages.
Major market players included in this report are:
Tilray
Aurora Cannabis
Canopy Growth Corporation
Aphria, Inc.
Maricann Group, Inc.
Tikun Olam, Ltd.
MedReleaf. Corp.
GW Pharmaceuticals plc.
Cannabis Sativa, Inc.
Medical Marijuana, Inc.
Recent Developments in the Market:
Global Medical Marijuana Market Report Scope:
Historical Data: 2019-2020-2021
Base Year for Estimation: 2021
Forecast period: 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Formulation Type, Application, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Formulation Type:
Capsules
Oils
Other Formulation Types
By Application:
Chronic Pain
Arthritis
Migraine
Cancer
Other Applications
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
List of figures
List of tables and figures and dummy in nature, final lists may vary in the final deliverable